NCT04871685

The ECOVITA Study - Validation of LUS Score in SARS-CoV-2 Disease, i.e COVID-19

ECOVITA Study. Observational Study on Sars-COV 2 Population Hospitalized in the Italian Country

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 950 (actual)
• Sponsor: University of Campania Luigi Vanvitelli · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Lung Ultrasound (LUS) has been revealing an extremely useful tool to identify and monitor complications from Sars-COV-2 disease. Recently, a research group has proposed a score, named LUS Score, able to optimize the use of this diagnostic technique. LUS Score is computed analyzing chest posterior and lateral spaces, considering the number of artefacts generated by the inflammed interstitium (B lines), the characteristics of the pleural line and the presence or not of consolidation areas. The comparison between LUS and chest tomography (CT), the current gold standard for the diagnosis of interstitial pneumonia by COVID-19, has confirmed from the preliminary data, the reliability of such technique. Hence, the validation on a really large sample size of the ultrasound tool performed by dedicated personnel with high expertise, may allow the validation both in the clinical practice and in emergency and ordinary wards.

Conditions

• Respiratory Distress Syndrome

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	lung ultrasound	the patients underwent to a non invasive diagnostic exam to identify and monitor clinical conditions and onset of respiratory complications due to COVID-19

Timeline

• Start date: 2020-10-18
• Primary completion: 2021-04-24
• Completion: 2021-05-03
• First posted: 2021-05-04
• Last updated: 2021-05-04

Locations

1 site across 1 country: Italy